 Home > Biochemistry News > Biotechnology News > CRISPR gene editing improved and innovative CAR-T therapy was recognized by the FDA as an advanced therapy for regenerative medicine

CRISPR gene editing improved and innovative CAR-T therapy was recognized by the FDA as an advanced therapy for regenerative medicine

 Last Update: 2022-01-01
 Source: Internet
 Author: User

Tags

medicine menstrual pain

carbon

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On November 22, 2021, CRISPR Therapeutics announced that the US FDA has granted CTX110 Regenerative Medicine Advanced Therapy (RMAT) designation

CTX110 locates the chimeric antigen receptor (CAR) targeting CD19 antigen into the cell's natural T cell receptor (TCR) site, and prevents the expression of endogenous TCR while introducing the CAR, thereby preventing graft-versus-host The occurrence of disease (GvHD)

▲Introduction to CTX110 (picture source: CRISPR Therapeutics official website)

The ongoing multi-center, open-label phase 1 clinical trial aims to evaluate the safety and effectiveness of multiple dose levels of CTX110 in the treatment of relapsed/refractory B-cell malignancies

▲Efficacy data of phase 1 clinical trial of CTX110 (picture source: reference [2])

Reference materials:

[1] CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110™ for the Treatment of Relapsed or Refractory CD19+ B-cell malignancies.

[2] CRISPR Therapeutics Reports Positive Results from its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell malignancies.

(The original text has been deleted)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Express CRISPR gene editing and improvement, innovative CAR-T therapy was recognized by the FDA as an advanced therapy for regenerative medicine

12-05

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

CRISPR gene editing improved and innovative CAR-T therapy was recognized by the FDA as an advanced therapy for regenerative medicine

Related Articles

Express CRISPR gene editing and improvement, innovative CAR-T therapy was recognized by the FDA as an advanced therapy for regenerative medicine